COVID-19: Hydroxychloroquine not suitable to treat disease – IDSA
The group recommends treatment with the combination of lopinavir/ritonavir only in the context of a clinical trial.
The group recommends treatment with the combination of lopinavir/ritonavir only in the context of a clinical trial.
Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |